Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis

Abstract

While 1 to 2% of amyotrophic lateral sclerosis (ALS) is caused by mutations in the SOD1 gene, the basis of the remaining instances of inherited disease is unknown. Neuropathology, mouse modeling, and human genetics have implicated neurofilaments in the pathogenesis of motor neuron diseases such as ALS and Charcot–Marie–Tooth disease (CMT). A systematic analysis of the coding region and intron–exon boundaries of all three neurofilament genes is now reported from DNA samples derived from more than 200 non-SOD1 linked familial and sporadic ALS patients, along with >400 non-disease control individuals. Rare variants within each of the three neurofilament subunits that are predicted to affect neurofilament assembly properties were identified at higher frequency in non-SOD1 mutant ALS samples. However, none could be unambiguously linked to dominantly inherited disease. Thus, mutations in neurofilaments are possible risk factors that may contribute to pathogenesis in ALS in conjunction with one or more additional genetic or environmental factors, but are not significant primary causes of ALS.

Introduction

Amyotrophic lateral sclerosis (ALS) is a prominent progressive adult motor neuron disease, accounting for about 1 in 2000 deaths. It is characterized by loss of both upper and lower motor neurons. To date, mutations in only two genes [the Cu/Zn superoxide dismutase (SOD1) gene and a gene encoding a vesicle-associated protein (VAPB); Nishimura et al., 2004] have been unequivocally demonstrated to lead to the familial form of ALS. SOD1 mutants account for 20–25% of dominantly inherited ALS (FALS) cases (Rosen et al., 1993); VAPB mutations have been identified in 7 families (Nishimura et al., 2004). Mutations in two other genes have been linked to two forms of rare juvenile motor neuron disease. These include mutations within a guanine exchange factor (GEF) on chromosome 2q33 that yield a very rare infantile or recessive disease that has been named ALS2, despite its atypical early onset, predominance of corticospinal signs and slow progression (Yamanaka et al., 2003, Zhao et al., 2001). Moreover, mutation in the senataxin gene causes an autosomal dominant, juvenile-onset, slowly progressive motor neuron disease designated ALS4 (Blair et al., 2000, Chen et al., 2004, Moreira et al., 2004).

A long known pathological hallmark of both familial and sporadic ALS is the formation of cytoplasmic inclusions within neuronal cell bodies (Hirano, 1991, Hirano et al., 1984a, Hirano et al., 1984b) and axoplasmic inclusions (Carpenter, 1968) containing disorganized masses of neurofilaments. More recently, another intermediate filament subunit, peripherin, has also been seen in these aggregates (Leung et al., 2004, Robertson et al., 2003). Several lines of additional evidence have suggested that intermediate filament disorganization and/or aggregation is central to motor neuron disease progression and not simply a consequence of a degenerating motor neuron. Neurofilament disorganization is an apparently early event in human disease (Hirano, 1991). Mouse models that either over-express wild type intermediate filaments (Beaulieu et al., 1999, Cote et al., 1993, Xu et al., 1993) or accumulate modest amounts, relative to endogenous, of a point mutant in NF-L (Lee et al., 1994) lead to selective degeneration of spinal motor neurons accompanied by abnormal accumulations of neurofilaments and severe neurogenic atrophy of skeletal muscles. In humans, alterations in the highly repetitive KSP repeat domain of NF-H have been proposed as risk factors for ALS (Al-Chalabi et al., 1999, Figlewicz et al., 1994, Tomkins et al., 1998), and mutations in NF-L have been linked to Charcot–Marie–Tooth disease type 2E (CMT2E) (De Jonghe et al., 2001, Jordanova et al., 2003, Mersiyanova et al., 2000, Yoshihara et al., 2002). Moreover, when expressed in cell culture, CMT2E mutant forms of NF-L can alter the assembly and transport of neurofilaments (Brownlees et al., 2002, Perez-Olle et al., 2004, Perez-Olle et al., 2002, Perez-Olle et al., 2005).

Neurofilaments are the most abundant structural component of large myelinated axons, and are obligate heteropolymers of NF-L and NF-M or NF-H (Ching and Liem, 1993, Lee et al., 1993). Mature spinal neurofilaments are composed of approximately a 5:3:1 ratio of NF-L, NF-M, and NF-H, respectively, with the head and rod domains of all three subunits constituting the neurofilament backbone and the long tail domains of NF-M and NF-H forming cross-links between other cytoskeletal proteins (Chen et al., 2000, Garcia et al., 2003, Rao et al., 2002). As with most neuronal proteins, neurofilaments are thought to be synthesized in the soma, and then subsequently transported into the axon via slow axonal transport. Once in the axon, neurofilaments are extremely long-lived proteins and are necessary for establishing and maintaining the three-dimensional array of axoplasm required for determining mature axonal diameter in myelinated regions of axons (Garcia et al., 2003, Ohara et al., 1993, Xu et al., 1996, Zhu et al., 1997). Altering subunit stoichiometry, or the complete loss of neurofilament accumulation in the axon, can significantly enhance survival in several well-established mouse models of SOD1 linked FALS (Couillard-Despres et al., 2000, Couillard-Despres et al., 1998, Eyer et al., 1998, Kong and Xu, 2000, Nguyen et al., 2000, Nguyen et al., 2001, Williamson et al., 1998), further implicating neurofilaments in the pathogenesis of ALS.

Previous examination of the coding regions of the NF-L, NF-M, and NF-H genes by single strand conformational polymorphism failed to identify sequence variants linked to disease (Vechio et al., 1996). With the discovery of causative, dominant mutants of NF-L in CMT type II (De Jonghe et al., 2001, Georgiou et al., 2002, Jordanova et al., 2003, Mersiyanova et al., 2000, Yoshihara et al., 2002), combined with neurofilament pathology seen in ALS and the effects of neurofilaments in accelerating SOD1-mediated disease, we have re-examined the possible genetic role of mutations within the neurofilament genes in ALS by direct sequencing of the coding regions and intron–exon boundaries of all three neurofilament genes from 300 DNA samples equally divided into familial ALS, sporadic ALS, and neurologically normal age-matched controls.